Targeted protein degradation (TPD) is a promising approach in drug discovery for degrading
proteins implicated in diseases. A key step in this process is the formation of a ternary …

The field of targeted protein degradation (TPD) has grown exponentially over the past
decade with the goal of developing therapies that mark proteins for destruction leveraging …

Degraders have illustrated that compound‐induced proximity to E3 ubiquitin ligases can
prompt the ubiquitination and degradation of disease‐relevant proteins. Hence, this …

The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due
to its potentially superior effects compared with protein inhibition. Recent advancements in …

Targeted protein degradation has become a reliable tool in the medicinal chemist's toolbox,
as seen with rapid progression of PROTACs (proteolysis targeting chimeras) to clinic …

PROteolysis TArgeting Chimeras (PROTACs) are hetero-bifunctional small molecules that
can simultaneously recruit target proteins and E3 ligases to form a ternary complex …

Targeted protein degradation via “hijacking” of the ubiquitin-proteasome system using
proteolysis targeting chimeras (PROTACs) has evolved into a novel therapeutic modality …

Bispecific protein degraders (BPDs) engage the ubiquitin–proteasome system (UPS) to
catalytically degrade intracellular proteins through the formation of ternary complexes with …

Only around 20% of the human proteome is considered to be druggable with small-molecule
antagonists. This leaves some of the most compelling therapeutic targets outside the reach …

Targeted protein degradation is a rapidly exploding drug discovery strategy that uses small
molecules to recruit disease-causing proteins for rapid destruction mainly via the ubiquitin …